Alzheimer’s disease doesn’t arrive suddenly. Instead, it emerges slowly, beginning with subtle changes that might be dismissed as normal aging before progressing through increasingly serious stages of ...

A team of researchers at the Sant Pau Research Institute (IR Sant Pau) has demonstrated that the plasma biomarker p-tau217, obtained through a simple blood test, can predict the clinical progression ...

The final stages of Alzheimer’s disease represent one of the most challenging periods for families watching their loved ones navigate this devastating condition. Understanding the critical signs that ...

The damage caused by Alzheimer's disease begins long before any symptoms show up. Over the course of years or decades in this preclinical stage, the characteristic buildup of disease-causing amyloid ...

A study conducted by The Hong Kong University of Science and Technology (HKUST) has demonstrated that a genetic variant, ...

Older Americans want to know if they are in the early stages of Alzheimer's disease and would happily take a blood test to find out, according to a national survey. The survey of 1,700 people 45 and ...

Alzheimer’s disease medicines typically help reduce and manage symptoms. They do not treat the cause of Alzheimer’s disease. Kisunla offers a new approach to treat early Alzheimer’s disease. It ...

Medications like lecanemab (Leqembi) and donanemab (Kisunla) target amyloid plaques in the brain that build up due to Alzheimer’s disease. They may help slow disease progression for people in the ...

Nearly 7 million Americans have Alzheimer's disease, and this number is predicted to double by 2060. While aging and genetic predisposition are the most important risk factors for Alzheimer's, ...